Last reviewed · How we verify
US Remicade
At a glance
| Generic name | US Remicade |
|---|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
- A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE) (PHASE3)
- Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
- Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects (PHASE1)
- A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US Remicade CI brief — competitive landscape report
- US Remicade updates RSS · CI watch RSS
- Samsung Bioepis Co., Ltd. portfolio CI